Hansa BioPharma licences Sarepta to develop imlifidase as a potential pre-treatment prior to the administration of gene therapy for muscular dystrophy patients.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest